Arbutus Imdusiran Combo Achieves Sustained Undetectable HBsAg in Hep B Short Course

 

• At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were maintained in 100% of these patients 24 weeks after completing imdusiran and IFN treatment
• Of the patients who have stopped all therapy, six still have undetectable levels of HBsAg and HBV DNA, with two of these patients reaching 12 weeks off all therapy
• All six patients have seroconverted and have high titers of anti-HBsAg antibodies
• These new Phase 2a data were presented at the European Association for the Study of the Liver (EASL) Congress 2024

https://www.biospace.com/article/releases/arbutus-imdusiran-with-short-course-interferon-achieves-sustained-undetectable-hbsag-a-necessity-for-hbv-functional-cure/